<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914626</url>
  </required_header>
  <id_info>
    <org_study_id>USaoPauloGH 294.326</org_study_id>
    <nct_id>NCT02914626</nct_id>
  </id_info>
  <brief_title>Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study</brief_title>
  <official_title>Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEANDRO CABRAL ZACHARIAS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neovascular glaucoma is a potentially blinding condition characterized by the growth of
      newvessels at the anterior part of the eye. This growth is driven by the overexpression of a
      protein called Vascular Endothelial Growth Factor (VEGF). That happens in diseases such as
      diabetic retinopathy or venous retinal occlusion, and lead to a fast increase in intraocular
      pressure (IOP). Traditional treatment include laser photocoagulation of the retina in order
      to decrease VEGF formation. The investigators postulate that the use of anti-VEGF
      intravitreal injections may accelerate recovery and decrease the need of surgery in cases of
      neovascular glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized controlled study that aims to evaluate the efficacy of
      ranibizumab (Lucentis®) as an adjunct in the treatment of patients with neovascular glaucoma.

      28 patients with neovascular glaucoma (14 in the study group and 14 in the control standard
      of care group) will be recruited at a single center- University of Sao Paulo Medical School
      General Hospital. A complete ophthalmologic exam will be carried out, including the obtention
      of an informed consent for eligible patients willing to participate on the study.

      Patients will be randomly assigned to either standard of care- retinal laser photocoagulation
      and clinical management of intraocular pressure with drops, or standard of care plus
      intravitreal ranibizumab injections. Two injections will be performed 30 days apart. The
      patients will be followed for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anterior segment neovascularization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drugs needed for IOP control</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for IOP control surgery</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Glaucoma, Neovascular</condition>
  <condition>Ranibizumab</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care therapy plus intravitreal ranibizumab injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Standard of care therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal ranibizumab</intervention_name>
    <description>Intravitreal ranibizumab injection</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IOP greater than 24 mmHg

          -  Iris or anterior chamber neovascularization

          -  At least 120 degrees of opened anterior chamber angle

        Exclusion Criteria:

          -  Visual acuity worse than counting fingers in the fellow eye

          -  No light perception in the treated eye

          -  Any ocular infectious disease

          -  Use of systemic steroids

          -  Lack of media transparency precluding laser photocoagulation

          -  Thromboembolic disease

          -  Known hypersensitivity to ranibizumab

          -  Female participants at childbearing age not using oral contraceptives

          -  Use of intravitreal anti-VEGF over the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leandro C Zacharias, MD, PhD</last_name>
    <phone>5511-2661-7871</phone>
    <email>lczacharias@gmail.com</email>
  </overall_contact>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>September 24, 2016</last_update_submitted>
  <last_update_submitted_qc>September 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>LEANDRO CABRAL ZACHARIAS</investigator_full_name>
    <investigator_title>Attending - Department of Ophthalmology- University of Sao Paulo</investigator_title>
  </responsible_party>
  <keyword>Glaucoma, Neovascular</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Intraocular pressure</keyword>
  <keyword>anti-VEGF</keyword>
  <keyword>intravitreal injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

